Literature DB >> 26945694

Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics.

Jennifer L Sargent1, Zhenghui Li1, Antonios O Aliprantis2, Matthew Greenblatt2, Raphael Lemaire3, Ming-Hua Wu4, Jun Wei4, Jaclyn Taroni1, Adam Harris5, Kristen B Long6, Chelsea Burgwin6, Carol M Artlett6, Elizabeth P Blankenhorn6, Robert Lafyatis3, John Varga4, Stephen H Clark5, Michael L Whitfield1.   

Abstract

OBJECTIVE: Understanding the pathogenesis of systemic sclerosis (SSc) is confounded by considerable disease heterogeneity. Animal models of SSc that recapitulate distinct subsets of disease at the molecular level have not been delineated. We applied interspecies comparative analysis of genomic data from multiple mouse models of SSc and patients with SSc to determine which animal models best reflect the SSc intrinsic molecular subsets.
METHODS: Gene expression measured in skin from mice with sclerodermatous graft-versus-host disease (GVHD), bleomycin-induced fibrosis, Tsk1/+ or Tsk2/+ mice was mapped to human orthologs and compared to SSc skin biopsy-derived gene expression. Transforming growth factor β (TGFβ) activation was assessed using a responsive signature in mice, and tumor necrosis factor receptor superfamily member 12A (TNFRSF12A) expression was measured in SSc patient and mouse skin.
RESULTS: Gene expression in skin from mice with sclerodermatous GVHD and bleomycin-induced fibrosis corresponded to that in SSc patients in the inflammatory molecular subset. In contrast, Tsk2/+ mice showed gene expression corresponding to the fibroproliferative SSc subset. Enrichment of a TGFβ-responsive signature was observed in both Tsk2/+ mice and mice with bleomycin-induced skin fibrosis. Expression of TNFRSF12A (the TWEAK receptor/fibroblast growth factor-inducible 14) was elevated in skin from patients with fibroproliferative SSc and the skin of Tsk2/+ mice.
CONCLUSION: This study reveals similarities in cutaneous gene expression between distinct mouse models of SSc and specific molecular subsets of the disease. Different pathways underlie the intrinsic subsets including TGFβ, interleukin-13 (IL-13), and IL-4. We identify a novel target, Tnfrsf12a, with elevated expression in skin from patients with fibroproliferative SSc and Tsk2/+ mice. These findings will inform mechanistic and translational preclinical studies in SSc.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2016        PMID: 26945694      PMCID: PMC5695038          DOI: 10.1002/art.39658

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  49 in total

1.  TWEAK induces liver progenitor cell proliferation.

Authors:  Aniela Jakubowski; Christine Ambrose; Michael Parr; John M Lincecum; Monica Z Wang; Timothy S Zheng; Beth Browning; Jennifer S Michaelson; Manfred Baetscher; Manfred Baestcher; Bruce Wang; D Montgomery Bissell; Linda C Burkly
Journal:  J Clin Invest       Date:  2005-08-18       Impact factor: 14.808

2.  Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study.

Authors:  Chris T Derk; Carol M Artlett; Sergio A Jimenez
Journal:  Clin Rheumatol       Date:  2006-01-25       Impact factor: 2.980

3.  TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast.

Authors:  Alvaro C Ucero; Alberto Benito-Martin; Isabel Fuentes-Calvo; Beatriz Santamaria; Julia Blanco; Jose M Lopez-Novoa; Marta Ruiz-Ortega; Jesus Egido; Linda C Burkly; Carlos Martinez-Salgado; Alberto Ortiz
Journal:  Biochim Biophys Acta       Date:  2013-06-06

4.  The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.

Authors:  Carol M Artlett; Sihem Sassi-Gaha; Judy L Rieger; Alina C Boesteanu; Carol A Feghali-Bostwick; Peter D Katsikis
Journal:  Arthritis Rheum       Date:  2011-11

5.  IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice.

Authors:  Pamela Gasse; Caroline Mary; Isabelle Guenon; Nicolas Noulin; Sabine Charron; Silvia Schnyder-Candrian; Bruno Schnyder; Shizuo Akira; Valérie F J Quesniaux; Vincent Lagente; Bernhard Ryffel; Isabelle Couillin
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

6.  The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration.

Authors:  P J Christner; J Peters; D Hawkins; L D Siracusa; S A Jiménez
Journal:  Arthritis Rheum       Date:  1995-12

7.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

8.  The pathogenesis of bleomycin-induced pulmonary fibrosis in mice.

Authors:  I Y Adamson; D H Bowden
Journal:  Am J Pathol       Date:  1974-11       Impact factor: 4.307

9.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Authors:  Jason I Herschkowitz; Karl Simin; Victor J Weigman; Igor Mikaelian; Jerry Usary; Zhiyuan Hu; Karen E Rasmussen; Laundette P Jones; Shahin Assefnia; Subhashini Chandrasekharan; Michael G Backlund; Yuzhi Yin; Andrey I Khramtsov; Roy Bastein; John Quackenbush; Robert I Glazer; Powel H Brown; Jeffrey E Green; Levy Kopelovich; Priscilla A Furth; Juan P Palazzo; Olufunmilayo I Olopade; Philip S Bernard; Gary A Churchill; Terry Van Dyke; Charles M Perou
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

10.  Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis.

Authors:  Jo Nadine Fleming; Howard M Shulman; Richard A Nash; Pamela Y Johnson; Thomas N Wight; Allen Gown; Stephen M Schwartz
Journal:  PLoS One       Date:  2009-07-09       Impact factor: 3.240

View more
  12 in total

1.  An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.

Authors:  Flavia V Castelino; Gretchen Bain; Veronica A Pace; Katharine E Black; Leaya George; Clemens K Probst; Lance Goulet; Robert Lafyatis; Andrew M Tager
Journal:  Arthritis Rheumatol       Date:  2016-12       Impact factor: 10.995

2.  Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis.

Authors:  Jennifer J Chia; Tong Zhu; Susan Chyou; Dragos C Dasoveanu; Camila Carballo; Sha Tian; Cynthia M Magro; Scott Rodeo; Robert F Spiera; Nancy H Ruddle; Timothy E McGraw; Jeffrey L Browning; Robert Lafyatis; Jessica K Gordon; Theresa T Lu
Journal:  J Clin Invest       Date:  2016-10-10       Impact factor: 14.808

3.  The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib.

Authors:  Wenxia Wang; Swati Bhattacharyya; Roberta Goncalves Marangoni; Mary Carns; Kathleen Dennis-Aren; Anjana Yeldandi; Jun Wei; John Varga
Journal:  J Scleroderma Relat Disord       Date:  2019-08-07

4.  Effects of Immunoglobulins G From Systemic Sclerosis Patients in Normal Dermal Fibroblasts: A Multi-Omics Study.

Authors:  Aurélien Chepy; Solange Vivier; Fabrice Bray; Camille Ternynck; Jean-Pascal Meneboo; Martin Figeac; Alexandre Filiot; Lucile Guilbert; Manel Jendoubi; Christian Rolando; David Launay; Sylvain Dubucquoi; Guillemette Marot; Vincent Sobanski
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

5.  Self-Assembled Human Skin Equivalents Model Macrophage Activation of Cutaneous Fibrogenesis in Systemic Sclerosis.

Authors:  Mengqi Huang; Avi Smith; Matthew Watson; Rajan Bhandari; Lauren M Baugh; Irena Ivanovska; Trishawna Watkins; Irene Lang; Maria Trojanowska; Lauren D Black; Patricia A Pioli; Jonathan Garlick; Michael L Whitfield
Journal:  Arthritis Rheumatol       Date:  2022-05-30       Impact factor: 15.483

6.  Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin.

Authors:  Monique Hinchcliff; Diana M Toledo; Jaclyn N Taroni; Tammara A Wood; Jennifer M Franks; Michael S Ball; Aileen Hoffmann; Sapna M Amin; Ainah U Tan; Kevin Tom; Yolanda Nesbeth; Jungwha Lee; Madeleine Ma; Kathleen Aren; Mary A Carns; Patricia A Pioli; Michael L Whitfield
Journal:  J Invest Dermatol       Date:  2018-01-31       Impact factor: 8.551

7.  Stretching Reduces Skin Thickness and Improves Subcutaneous Tissue Mobility in a Murine Model of Systemic Sclerosis.

Authors:  Ying Xiong; Lisbeth Berrueta; Katia Urso; Sara Olenich; Igla Muskaj; Gary J Badger; Antonios Aliprantis; Robert Lafyatis; Helene M Langevin
Journal:  Front Immunol       Date:  2017-02-16       Impact factor: 7.561

8.  Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis.

Authors:  Swati Bhattacharyya; Wenxia Wang; Zenshiro Tamaki; Bo Shi; Anjana Yeldandi; Yasuhiro Tsukimi; Masashi Yamasaki; John Varga
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

9.  Selective deletion of PPARβ/δ in fibroblasts causes dermal fibrosis by attenuated LRG1 expression.

Authors:  Ming Keat Sng; Jeremy Soon Kiat Chan; Ziqiang Teo; Terri Phua; Eddie Han Pin Tan; Jonathan Wei Kiat Wee; Nikki Jun Ning Koh; Chek Kun Tan; Jia Peng Chen; Mintu Pal; Benny Meng Kiat Tong; Ya Lin Tnay; Xuan Rui Ng; Pengcheng Zhu; Shunsuke Chiba; Xiaomeng Wang; Walter Wahli; Nguan Soon Tan
Journal:  Cell Discov       Date:  2018-04-03       Impact factor: 10.849

10.  Prediction of severity and subtype of fibrosing disease using model informed by inflammation and extracellular matrix gene index.

Authors:  Amin M Cheikhi; Zariel I Johnson; Dana R Julian; Sarah Wheeler; Carol Feghali-Bostwick; Yvette P Conley; James Lyons-Weiler; Cecelia C Yates
Journal:  PLoS One       Date:  2020-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.